<DOC>
	<DOC>NCT00302666</DOC>
	<brief_summary>The aim of this study is to evaluate bleeding pattern, cycle control, contraceptive efficacy and safety of this oral contraceptive in two different regimens of intake.</brief_summary>
	<brief_title>Bleeding Pattern Study</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<criteria>Healthy female volunteers aged between 18 and 40 years requiring contraception. Pregnancy or lactation. Any conditions that might interfere with the outcome as well as all contraindications for OC use.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Contraception, Bleeding pattern</keyword>
</DOC>